HCC
Conditions
Interventions
research group 1:5mL nano methylene blue injection was injected through the hepatic portal vein
Control :5mL methylene blue injection was injected through the hepatic portal vein
research group 2:5mL of the nano-methylene blue-lipiodol compound was injected through the portal vein of the hepatic segment
Sponsors
Bishan District People's Hospital of Chongqing
Eligibility
Sex/Gender
All
Age
14 Years to 75 Years
Inclusion criteria
Inclusion criteria: All patients were diagnosed with primary liver cancer according to the 2022 NCCN guidelines for primary liver cancer diagnosis criteria. The patient is generally in good condition with liver function grade A to B and is expected to tolerate surgery. Indocyanine green excretion test (ICG) indicated that the clearance rate of ICG R15 was less than 15%.
Exclusion criteria
Exclusion criteria: Exclude patients with complicated organ dysfunction; Patients with other tumor diseases or surgical contraindications were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CT; | — |
Countries
China
Contacts
Public Contactzhang xiang
Bishan District People's Hospital of Chongqing
Outcome results
None listed